 |
|
Herpesvirus hominis EncephalitisNeurological Manifestations and Use of Idoxuridine
John Stirling Meyer, MD;
Raymond B. Bauer, MD;
Victor M. Rivera-Olmos, MD;
David C. Nolan, MD;
A. Martin Lerner, MD
Arch Neurol. 1970;23(5):438-450.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
BECAUSE of the high mortality of Herpesvirus hominis encephalitis and recent data suggesting that treatment should be considered, the real incidence of this disease is now important. This incidence remains unknown. However, on the basis of our experience, herpesvirus encephalitis is relatively common.1,2
Nolan and co-workers1 concluded that patients with H hominis encephalitis who are in coma (unresponsive to all external stimuli) or are having convulsions have a poor prognosis. Conversely, patients who are not in coma and do not have convulsions may survive intact. Interest in the possibility of therapy has been stimulated by five recent reports of individual patients with herpesvirus encephalitis who received idoxuridine.3-7 Apparently, about 60% of untreated and variably selected patients die.8-13 Patients who recover may sustain severe, permanent, neurological deficits which include intellectual deterioration, dystonia, and motor weakness.
Characteristics have been reported of the general medical illnesses of
. . . [Full Text PDF of this Article]
Author Affiliations
Detroit
From the Harper and Detroit General (Receiving) Hospitals, the departments of neurology (Dr. Bauer) and Medicine (Drs. Lerner and Nolan), Wayne State University School of Medicine, Detroit, and the Methodist Hospital and Department of Neurology (Drs. Meyer and Rivera-Olmos), Baylor College of Medicine, Houston.
Footnotes
Accepted for publication April 27, 1970.
Reprint requests to Department of Neurology, Baylor College of Medicine, 1200 Moursund, Houston 77025 (Dr. Meyer).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
